Weekly paclitaxel and gemcitabine chemotherapy for metastatic non‐small cell lung carcinoma (NSCLC)

The current dose‐optimizing Phase II study evaluated the effect of weekly paclitaxel and gemcitabine on the response rate and survival of patients with non‐small cell lung carcinoma (NSCLC) using dose modifications that permitted optimal treatment intensity.

[1]  Y. Cormier,et al.  Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma , 2001, Cancer.

[2]  I. Vlachonikolis,et al.  Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial , 2001, The Lancet.

[3]  R. Rosell,et al.  Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (gv/iv) in advanced non-small cell lung cancer (NSCLC): final results of a Spanish lung cancer group phase III trial (GEPC/98-02) , 2001 .

[4]  E. Smit,et al.  An EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer , 2001 .

[5]  R. Stephens,et al.  Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome , 2000, British Journal of Cancer.

[6]  S. Palazzo,et al.  Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Hausamen,et al.  Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. , 1996, Seminars in oncology.

[8]  W. Akerley.  Phase I/II trial of weekly paclitaxel in patients with advanced lung cancer. , 1996, Seminars in oncology.

[9]  F. Shepherd,et al.  Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. , 1996, European journal of cancer.

[10]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[11]  W. Bezwoda,et al.  Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Kaasa,et al.  Polychemotherapy in advanced non small cell lung cancer: a meta-analysis , 1993, The Lancet.

[13]  G. van Kaick,et al.  New aspects in the staging of lung cancer. Prospective validation of the international union against cancer TNM classification , 1992, Cancer.

[14]  P. Warde,et al.  Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J L Pater,et al.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Hooper.  The Vaccination Bill , 1840 .